Amgen Inc
Amgen Inc. discovers, develops, manufactures and commercializes prescription biologic and small‑molecule medicines across multiple therapeutic areas, operating as a single segment (human therapeutics). The company’s business model combines in-house R&D and biologics manufacturing with global commercialization, with product demand shaped by regulatory approvals and payer reimbursement. Amgen sells primarily through pharmaceutical wholesalers in the U.S. and through a mix of wholesalers and direct-to-provider channels internationally, supported by collaborations in certain markets. Its portfolio includes established brands (e.g., Prolia, Repatha, ENBREL) alongside newer growth products and a pipeline that targets high unmet medical need.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePrimary care and specialty medicines including bone health, lipid management and immunology/inflammation brands.
Cancer and blood-disorder therapies sold through oncology/hematology channels and hospitals.
Specialty and rare-disease products often requiring specialist prescribing and payer authorization.
Non-product revenues such as collaboration-related income and other ancillary items.
Customers
Amgen’s end customers are healthcare providers and patients, but its direct customers in the U.S. are predominantly large pharmaceutical wholesale distributors that supply pharmacies, hospitals, clinics and other care sites. McKesson, Cencora and Cardinal Health together represent the majority of worldwide gross revenues, giving these intermediaries significant purchasing leverage and making channel dynamics important to pricing and volumes. Demand and net realized price are heavily influenced by government and commercial payers, including PBMs that negotiate rebates and formulary placement and can shift share to competing therapies. Outside the U.S., Amgen sells through a mix of wholesalers and direct-to-provider channels depending on local distribution practices, and it also uses collaborations/partners in parts of Asia Pacific and for certain products (e.g., TEZSPIRE ex-U.S.).
Purchase large volumes for downstream distribution; central to U.S. channel access and working-capital dynamics.
Determine coverage, reimbursement and patient access; negotiate rebates/discounts that drive net price.
Prescribe and administer therapies (especially oncology and infused/injectable products) and influence product adoption.
Buy products under country-specific distribution models; growth depends on local access and partner execution.
Co-commercialize or commercialize in specific territories/products (e.g., TEZSPIRE ex-U.S.), affecting reach and economics.
Strategy
Amgen’s strategy centers on investing in innovation (internal R&D and external business development) while scaling manufacturing capacity to support both marketed products and pipeline assets. The company allocates capital across R&D, capacity expansion, debt repayment, dividends and share repurchases, reflecting a balance between growth investment and shareholder returns. Commercially, it seeks to expand indications and labels for existing brands (e.g., Repatha’s broadened FDA-approved use) to widen eligible patient populations and improve access. Internationally, Amgen uses a mix of direct affiliates and collaborations to reach markets where local scale, regulatory pathways or distribution practices favor partnering.
Biologics supply reliability underpins revenue and launch execution; site concentration heightens the need for resilience.
Label expansions and new indications can extend product life and increase volume without full new-product risk.
Biopharma revenue durability depends on replenishing products facing competition and pricing pressure.
Geography
2025Amgen markets products globally with a presence in approximately 100 countries, but product sales are concentrated in the United States. Authoritative disclosures show 2025 product sales of $25,656 million (73%) in the U.S. and $9,492 million (27%) in the rest of world (ROW), consistent with 2024 (73%/27%) and 2023 (72%/28%). Commercial operations are concentrated in the U.S. and Europe, while the company also sells in Japan, China and other parts of Asia, Latin America and the Middle East through affiliates, acquisitions of rights, and collaborations. Manufacturing footprint concentration is a key geographic exposure: a substantial majority of commercial manufacturing is in Puerto Rico and a substantial majority of clinical manufacturing is in Thousand Oaks, California.
Share of the revenue the company reports by geography.
Risks
Amgen’s revenue is exposed to payer coverage and reimbursement decisions, with pricing pressure amplified by consolidation among PBMs and wholesalers that can demand higher rebates/discounts or shift volume to competitors. The company faces development and regulatory risk because product candidates and new indications require clinical trials and regulatory approvals, and some products rely on companion diagnostics or delivery devices with their own compliance risks. Operationally, manufacturing concentration in Puerto Rico (commercial) and Thousand Oaks (clinical) creates single-site disruption risk, compounded by reliance on certain sole-source third-party suppliers for raw materials and components. International operations add exposure to tariffs, trade measures, foreign exchange and geopolitical disruptions, while cybersecurity incidents at third-party service providers can create data, operational and compliance risks.
- Manufacturing disruption at key sitesImpact: CriticalLikelihood: Medium
A substantial majority of commercial manufacturing is in Puerto Rico and clinical manufacturing in Thousand Oaks; disruptions could impair supply and trials.
Exposure: Puerto Rico and California facilities
- Coverage, reimbursement and pricing pressure from payers/PBMsImpact: HighLikelihood: High
Government and commercial payers influence access and net price; PBM consolidation increases negotiating leverage and risk of exclusion.
Exposure: U.S. market (largest revenue concentration)
- Customer concentration in three U.S. wholesalersImpact: HighLikelihood: High
McKesson, Cencora and Cardinal Health each exceed 10% of revenues; combined ~77% of worldwide gross revenues, increasing bargaining power and credit exposure.
Exposure: Distribution channel / working capital
- Third-party supplier dependency (including sole-source inputs)Impact: HighLikelihood: Medium
Certain raw materials, devices and components are proprietary to unaffiliated suppliers; shortages/quality issues can constrain production.
Exposure: Supply chain
- Cybersecurity incidents at third-party service providersImpact: MediumLikelihood: Low
Supplier breaches have occurred with unauthorized access/exfiltration; delayed or incomplete incident reporting can impair response and increase impact.
Exposure: Third-party IT/service ecosystem
Accounting
Judgemental itemsRevenue is recorded net of estimated deductions established at sale and adjusted quarterly; changes in assumptions/actuals affect net sales and liabilities.
Impact: Net product sales, accrued liabilities, period-to-period volatility
Impairment assessments require judgment about future cash flows and market conditions; charges can be material and non-recurring.
Impact: Operating income and asset carrying values
Similar listed companies
Publicly listed companies with a comparable business focus.
AstraZeneca PLC
AZN · Pharmaceutical Preparations
AstraZeneca PLC is a global biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines.
Amneal Pharmaceuticals, Inc.
AMRX · Pharmaceutical Preparations
Amneal Pharmaceuticals is a U.S.-based diversified biopharmaceutical company that develops, manufactures, markets, and distributes essential medicines across…
Biogen Inc
BIIB · Biological Products, (No Diagnostic Substances)
Biogen is a U.S.-based biopharmaceutical company built around therapies for serious neurological, immunological and rare diseases.
Cigna Group
CI · Hospital & Medical Service Plans
Cigna Group is a U.S.-based global health company that combines health benefits and pharmacy/medical services through two core segments: Cigna Healthcare and Evernorth Health Services.
Inogen Inc
INGN · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Inogen Inc designs, markets, and sells portable and stationary oxygen concentrators and related respiratory products for people needing long-term oxygen therapy.
Compugen Ltd
CGEN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026